Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: June 29, 2022

Details for New Drug Application (NDA): 207620

✉ Email this page to a colleague

« Back to Dashboard

NDA 207620 describes ENTRESTO, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the ENTRESTO profile page.

The generic ingredient in ENTRESTO is sacubitril; valsartan. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sacubitril; valsartan profile page.
Summary for 207620
Applicant:Novartis Pharms Corp
Ingredient:sacubitril; valsartan
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 207620
Generic Entry Date for 207620*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 207620
Suppliers and Packaging for NDA: 207620
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ENTRESTO sacubitril; valsartan TABLET;ORAL 207620 NDA Novartis Pharmaceuticals Corporation 0078-0659 0078-0659-20 60 TABLET, FILM COATED in 1 BOTTLE (0078-0659-20)
ENTRESTO sacubitril; valsartan TABLET;ORAL 207620 NDA Novartis Pharmaceuticals Corporation 0078-0659 0078-0659-67 180 TABLET, FILM COATED in 1 BOTTLE (0078-0659-67)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength24MG;26MG
Approval Date:Jul 7, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 16, 2024
Regulatory Exclusivity Expiration:Oct 1, 2022
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Apr 1, 2023
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.